News

Model Grant Agreements Unit Cost and Lump Sum published

Published on | 4 years ago

Programmes
MSCA HorizonEU L+F

On the Funding&Tender Portal (reference documents) - 2 new Model Grant Agreements (MGA) for Horizon Europe have been published (besides the "general" MGA already available) :

  • The Unit MGA for HE, including
    • the MSCA specificities
    • provisions for ERA Fellowships which are similar with MSCA Post-Doctoral Fellowships (PF) the only difference being that the Fellows are called ‘ERA Fellows’ and not ‘MSCA fellows’
  • The Lump Sum MGA

The Annotated MGA has not yet been published and as explained in the MGA workshop of the R&I days (23.06.2021) this will be published in July in a fragmented way, with the aim that it is completely published by September.

 

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1899 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.